Eolas

Eolas Therapeutics was a clinical-stage biotechnology company focused on the development of novel small molecule treatments for neuropsychiatric disorders, particularly substance use disorders. The company's lead candidate, Eolas-001, is a selective Orexin-1 receptor antagonist aimed at reducing the craving and relapse associated with opioid and cocaine addiction. Eolas was established as a spin-out from the University of Sydney and the Florey Institute of Neuroscience and Mental Health in Australia. The company leveraged specialized expertise in the orexin system to address the unmet medical needs of patients struggling with chemical dependency. In early 2020, the company was acquired by Eli Lilly to integrate its orexin-based programs into Lilly's broader neuroscience portfolio. This acquisition allowed for the continued clinical development of their lead assets within a major pharmaceutical infrastructure.